Erlotinib and Sunitinib in NSCLC

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
University of Wisconsin, Madison
Study ID
NCT00581789
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • erlotinib, sunitinib — DRUG
    erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)

Study Details

* To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC). * To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.

Key Dates

First listed
Dec 28, 2007
Start date
Aug 31, 2007
Status verified
Feb 2012
Primary completion
Feb 28, 2010
Completion
Aug 31, 2011

Study Design

Enrollment
11 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)

Primary Outcome Measure

Safety [ Time Frame: 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Wisconsin Carbone Comprehensive Cancer CenterMadisonWisconsin53792-

Find similar trials in Madison, WI

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of Wisconsin Carbone Comprehensive Cancer Center· Madison, WI

Related Studies